Leucine-Rich Repeat Kinase 2 Regulates the Progression of Neuropathology Induced by Parkinson's-Disease-Related Mutant α-synuclein

Neuron

Volumn 64, Issue 6, 2009, Pages 807-827

  Lin, Xian ^a   Parisiadou, Loukia ^a   Gu, Xing Long ^a   Wang, Lizhen ^a   Shim, Hoon ^a   Sun, Lixin ^a   Xie, Chengsong ^a   Long, Cai Xia ^a   Yang, Wan Jou ^a   Ding, Jinhui ^a   Chen, Zsu Zsu ^e   Gallant, Paul E ^b   Tao Cheng, Jung Hwa ^b   Rudow, Gay ^f   Troncoso, Juan C ^f   Liu, Zhihua ^c   Li, Zheng ^d   Cai, Huaibin ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HUMDISEASE; MOLNEURO; SYSNEURO

Indexed keywords

ALPHA SYNUCLEIN; LEUCINE RICH REPEAT TRANSMEMBRANE PROTEIN 2; MEMBRANE PROTEIN; MUTANT PROTEIN; PROTEASOME; UBIQUITIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GOLGI COMPLEX; MICROTUBULE ASSEMBLY; MOUSE; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING;

ALPHA-SYNUCLEIN; ANIMALS; BRAIN; DISEASE PROGRESSION; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; GOLGI APPARATUS; INCLUSION BODIES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROTUBULES; MUTATION; NERVE DEGENERATION; NEURONS; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES;

EID: 72149087091     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuron.2009.11.006     Document Type: Article

References (53)

1. Arlotta P., Molyneaux B.J., Jabaudon D., Yoshida Y., and Macklis J.D. Ctip2 controls the differentiation of medium spiny neurons and the establishment of the cellular architecture of the striatum. J. Neurosci. 28 (2008) 622-632
2. Biskup S., Moore D.J., Celsi F., Higashi S., West A.B., Andrabi S.A., Kurkinen K., Yu S.W., Savitt J.M., Waldvogel H.J., et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol. 60 (2006) 557-569
3. Conway K.A., Harper J.D., and Lansbury P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4 (1998) 1318-1320
4. Cooper A.A., Gitler A.D., Cashikar A., Haynes C.M., Hill K.J., Bhullar B., Liu K., Xu K., Strathearn K.E., Liu F., et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313 (2006) 324-328
5. Cuervo A.M., Stefanis L., Fredenburg R., Lansbury P.T., and Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305 (2004) 1292-1295
6. Galter D., Westerlund M., Carmine A., Lindqvist E., Sydow O., and Olson L. LRRK2 expression linked to dopamine-innervated areas. Ann. Neurol. 59 (2006) 714-719
7. Gandhi P.N., Wang X., Zhu X., Chen S.G., and Wilson-Delfosse A.L. The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J. Neurosci. Res. 86 (2008) 1711-1720
8. Gilks W.P., Abou-Sleiman P.M., Gandhi S., Jain S., Singleton A., Lees A.J., Shaw K., Bhatia K.P., Bonifati V., Quinn N.P., et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365 (2005) 415-416
9. Gillardon F. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability - a point of convergence in Parkinsonian neurodegeneration?. J. Neurochem. 110 (2009) 1514-1522
10. Gong S., Zheng C., Doughty M.L., Losos K., Didkovsky N., Schambra U.B., Nowak N.J., Joyner A., Leblanc G., Hatten M.E., and Heintz N. A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425 (2003) 917-925
11. Gosavi N., Lee H.J., Lee J.S., Patel S., and Lee S.J. Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J. Biol. Chem. 277 (2002) 48984-48992
12. Greggio E., Jain S., Kingsbury A., Bandopadhyay R., Lewis P., Kaganovich A., van der Brug M.P., Beilina A., Blackinton J., Thomas K.J., et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 23 (2006) 329-341
13. Hardy J., Cai H., Cookson M.R., Gwinn-Hardy K., and Singleton A. Genetics of Parkinson's disease and parkinsonism. Ann. Neurol. 60 (2006) 389-398
14. Higashi S., Biskup S., West A.B., Trinkaus D., Dawson V.L., Faull R.L., Waldvogel H.J., Arai H., Dawson T.M., Moore D.J., and Emson P.C. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res. 1155 (2007) 208-219
15. Hsu L.J., Sagara Y., Arroyo A., Rockenstein E., Sisk A., Mallory M., Wong J., Takenouchi T., Hashimoto M., and Masliah E. alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157 (2000) 401-410
16. Imai Y., Gehrke S., Wang H.Q., Takahashi R., Hasegawa K., Oota E., and Lu B. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 27 (2008) 2432-2443
17. Ishihara T., Hong M., Zhang B., Nakagawa Y., Lee M.K., Trojanowski J.Q., and Lee V.M. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24 (1999) 751-762
18. Jaleel M., Nichols R.J., Deak M., Campbell D.G., Gillardon F., Knebel A., and Alessi D.R. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J. 405 (2007) 307-317
19. Jankowsky J.L., Slunt H.H., Gonzales V., Savonenko A.V., Wen J.C., Jenkins N.A., Copeland N.G., Younkin L.H., Lester H.A., Younkin S.G., and Borchelt D.R. Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med. 2 (2005) e355
20. Lee H.J., Patel S., and Lee S.J. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J. Neurosci. 25 (2005) 6016-6024
21. Lee H.J., Khoshaghideh F., Lee S., and Lee S.J. Impairment of microtubule-dependent trafficking by overexpression of alpha-synuclein. Eur. J. Neurosci. 24 (2006) 3153-3162
22. Li X., Tan Y.C., Poulose S., Olanow C.W., Huang X.Y., and Yue Z. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J. Neurochem. 103 (2007) 238-247
23. Li Y., Liu W., Oo T.F., Wang L., Tang Y., Jackson-Lewis V., Zhou C., Geghman K., Bogdanov M., Przedborski S., et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci. 12 (2009) 826-828
24. Liu Z., Wang X., Yu Y., Li X., Wang T., Jiang H., Ren Q., Jiao Y., Sawa A., Moran T., et al. A Drosophila model for LRRK2-linked parkinsonism. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 2693-2698
25. Maroteaux L., and Scheller R.H. The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Brain Res. Mol. Brain Res. 11 (1991) 335-343
26. Maroteaux L., Campanelli J.T., and Scheller R.H. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8 (1988) 2804-2815
27. Martin L.J., Pan Y., Price A.C., Sterling W., Copeland N.G., Jenkins N.A., Price D.L., and Lee M.K. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 26 (2006) 41-50
28. Mayford M., Bach M.E., Huang Y.Y., Wang L., Hawkins R.D., and Kandel E.R. Control of memory formation through regulated expression of a CaMKII transgene. Science 274 (1996) 1678-1683
29. Narhi L., Wood S.J., Steavenson S., Jiang Y., Wu G.M., Anafi D., Kaufman S.A., Martin F., Sitney K., Denis P., et al. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem. 274 (1999) 9843-9846
30. Nichols W.C., Pankratz N., Hernandez D., Paisan-Ruiz C., Jain S., Halter C.A., Michaels V.E., Reed T., Rudolph A., Shults C.W., et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 365 (2005) 410-412
31. Nussbaum R.L., and Polymeropoulos M.H. Genetics of Parkinson's disease. Hum. Mol. Genet. 6 (1997) 1687-1691
32. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., Lopez d.M., Aparicio S., Gil A.M., Khan N., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 (2004) 595-600
33. Parisiadou L., Xie C., Cho H.J., Lin X., Gu X.L., Long C.X., Lobbestael E., Baekelandt V., Taymans J.M., Sun L., and Cai H. Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J. Neurosci. 29 (2009) 13971-13980
34. Paxinos G., and Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates (Deluxe Edition of the Atlas) (2001), Academic Press, San Diego, CA
35. Robinson K.M., Janes M.S., Pehar M., Monette J.S., Ross M.F., Hagen T.M., Murphy M.P., and Beckman J.S. Selective fluorescent imaging of superoxide in vivo using ethidium-based probes. Proc. Natl. Acad. Sci. USA 103 (2006) 15038-15043
36. Roy S., Winton M.J., Black M.M., Trojanowski J.Q., and Lee V.M. Cytoskeletal requirements in axonal transport of slow component-b. J. Neurosci. 28 (2008) 5248-5256
37. Savitt J.M., Dawson V.L., and Dawson T.M. Diagnosis and treatment of Parkinson disease: molecules to medicine. J. Clin. Invest. 116 (2006) 1744-1754
38. Smith W.W., Pei Z., Jiang H., Dawson V.L., Dawson T.M., and Ross C.A. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 9 (2006) 1231-1233
39. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., and Goedert M. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
40. Tanaka Y., Engelender S., Igarashi S., Rao R.K., Wanner T., Tanzi R.E., Sawa A., Dawson L., Dawson T.M., and Ross C.A. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10 (2001) 919-926
41. Tao-Cheng J.H. Activity-related redistribution of presynaptic proteins at the active zone. Neuroscience 141 (2006) 1217-1224
42. Thyberg J., and Moskalewski S. Role of microtubules in the organization of the Golgi complex. Exp. Cell Res. 246 (1999) 263-279
43. Tong Y., Pisani A., Martella G., Karouani M., Yamaguchi H., Pothos E.N., and Shen J. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc. Natl. Acad. Sci. USA 106 (2009) 14622-14627
44. Trojanowski J.Q., Goedert M., Iwatsubo T., and Lee V.M. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differ. 5 (1998) 832-837
45. Valiron O., Caudron N., and Job D. Microtubule dynamics. Cell. Mol. Life Sci. 58 (2001) 2069-2084
46. Wang L., Xie C., Greggio E., Parisiadou L., Shim H., Sun L., Chandran J., Lin X., Lai C., Yang W.J., et al. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J. Neurosci. 28 (2008) 3384-3391
47. Wehland J., Henkart M., Klausner R., and Sandoval I.V. Role of microtubules in the distribution of the Golgi apparatus: effect of taxol and microinjected anti-alpha-tubulin antibodies. Proc. Natl. Acad. Sci. USA 80 (1983) 4286-4290
48. Weingarten M.D., Lockwood A.H., Hwo S.Y., and Kirschner M.W. A protein factor essential for microtubule assembly. Proc. Natl. Acad. Sci. USA 72 (1975) 1858-1862
49. West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A., Dawson V.L., and Dawson T.M. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. USA 102 (2005) 16842-16847
50. Westerlund M., Ran C., Borgkvist A., Sterky F.H., Lindqvist E., Lundstromer K., Pernold K., Brene S., Kallunki P., Fisone G., et al. Lrrk2 and alpha-synuclein are co-regulated in rodent striatum. Mol. Cell. Neurosci. 39 (2008) 586-591
51. Zabetian C.P., Samii A., Mosley A.D., Roberts J.W., Leis B.C., Yearout D., Raskind W.H., and Griffith A. A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 65 (2005) 741-744
52. Zhu X., Siedlak S.L., Smith M.A., Perry G., and Chen S.G. LRRK2 protein is a component of Lewy bodies. Ann. Neurol. 60 (2006) 617-618
53. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 (2004) 601-607